Read + Share
Bose S, Kalinsky K. Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily
Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer. Clin Breast Cancer 2020 Oct 14. pii: S1526-8209(20)30261.
PMID: 33177006
|
 |
|
Bose S, Kalinsky K. Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily
Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer. Clin Breast Cancer 2020 Oct 14. pii: S1526-8209(20)30261.
PMID: 33177006
|
|
|
|